Retrospective Study

Diagnosis and surgical treatment of esophageal gastrointestinal stromal tumors

Fang-Biao Zhang, Hong-Can Shi, Yu-Sheng Shu, Wei-Ping Shi, Shi-Chun Lu, Xiang-Yan Zhang, Shao-Song Tu

Abstract

AIM: To retrospectively evaluate our experience with the diagnosis and surgical resection of esophageal gastrointestinal stromal tumors (GISTs).

METHODS: Between January 2003 and August 2014, five esophageal GIST cases were admitted to our hospital. In this study, the hospital records, surgery outcomes, tumor recurrence and survival of these patients were retrospectively reviewed.

RESULTS: The median age of the patients was 45.6 years (range: 12-62 years). Three patients presented with dysphagia, and one patient presented with chest discomfort. The remaining patient was asymptomatic.

Four patients were diagnosed with esophageal GISTs by a preoperative endoscopic biopsy. Three patients underwent esophagectomy, and two patients underwent video-assisted thoracoscopic surgery. The mean operating time was 116 min (range: 95-148 min), and the mean blood loss was 176 mL (range: 30-300 mL). All tumors were completely resected. The mean length of postoperative hospital stay was 8.4 d (range: 6-12 d). All patients recovered and were discharged successfully. The median postoperative follow-up duration was 48 mo (range: 29-72 mo). One patient was diagnosed with recurrence, one patient was lost to follow-up, and three patients were asymptomatic and are currently being managed with close radiologic and clinical follow-up.

CONCLUSION: Surgery is the standard, effective and successful treatment for esophageal GISTs. Long-term follow-up is required to monitor recurrence and metastasis.

Key words: Esophagus; Gastrointestinal stromal tumors; Recurrence

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Gastrointestinal stromal tumors (GISTs) commonly occur in the stomach and small intestine but are less frequent in the esophagus. To our knowledge, there are few detailed reports concerning the diagnosis and surgical treatment of esophageal GISTs. The main purpose of the present study was to present our experience with the diagnosis and surgical resection of esophageal GISTs.

Zhang FB, Shi HC, Shu YS, Shi WP, Lu SC, Zhang XY, Tu SS. Diagnosis and surgical treatment of esophageal gastrointestinal stromal tumors. World J Gastroenterol 2015; 21(18): 5630-5634 Available from: URL: http://www.wjgnet.com/1007-9327/full/v21/i18/5630.htm DOI: http://dx.doi.org/10.3748/wjg.v21.i18.5630

INTRODUCTION

Gastrointestinal stromal tumors (GISTs) are common mesenchymal neoplasms arising from the digestive tract and abdomen and were initially described by Mazur and Clark[14] in 1983. Since their discovery, GISTs have been identified in a number of locations, including the esophagus, stomach, jejunum, ileum and colon[2-13]. Furthermore, according to a study by Miettinen[14], the most common sites of GISTs are the stomach (60%-70%) and small intestine (20%-30%)[14-16]. In contrast, esophageal GISTs are rare and account for fewer than 2% of all GISTs[17-19]. In the past, the origin of esophageal GISTs was initially reported to be smooth muscle[20]. However, following an immunohistochemical-analysis-based study, it has become well established that GISTs arise from pluripotent stem cells or interstitial cells[21].

We therefore analyzed the clinical features, histological and immunohistochemical characteristics of five cases of esophageal GISTs and reviewed our experience with the diagnosis and surgical treatment of patients with esophageal GISTs.

MATERIALS AND METHODS

Date was retrospectively retrieved for five patients who underwent surgical resection of GISTs at the Department of Thoracic Surgery, Clinical College of Yangzhou University, Yangzhou, China between January 2003 and August 2014. This retrospective study was approved by our Institutional Review Board, and waiver of consent was obtained. Standard preoperative work-up included routine blood routine examination, biochemical examination, chest and abdominal computed tomography (CT) scanning, esophageal barium meal, esophagoscopy and abdominal computed tomography (CT) scanning, esophageal barium meal, esophagoscopy and endoscopic ultrasound (EUS) for elective patients.

Clinicopathologic information form hospital records and the database of the clinical research institute, including patient gender, age, clinical presentation, location and size of lesions, operative time, operative findings, operative blood loss, tumor size, tumor characteristics (benign or malignant) and recurrence during routine follow-up were retrieved for all cases. The histological and immunohistochemical characteristics of the tumors, including CD34, CD117, Desmin, S-100 and SMA expression, were also reviewed. The diagnosis of malignant GISTs was made according to the previously published paper of Emory[17]. In brief, diagnostic criteria for GISTs were assessed for the presence of the following: (1) esophageal GISTs > 5.5 cm in diameter; (2) mitotic index > 5 mitotic figures/50 high-power fields; and (3) invasive behavior and metastasis.

RESULTS

Of the five cases, all were males, with a mean age of 45.6 years (range: 12-62 years). Four patients were symptomatic, three presented with dysphagia and one presented with chest discomfort. The remaining patient was asymptomatic. Four patients were preoperatively diagnosed with esophageal GISTs and one with esophageal leiomyoma by endoscopic biopsy. Representative findings from esophageal barium meals showed a larger tumor in the esophagus (Figure 1), and esophagoscopy revealed a large tumor in the esophagus (Figure 2). One, two and two tumors occurred in the upper, middle and lower third of the esophagus, respectively. Data of the clinical features are shown in Table 1.

All patients had no history of diabetes mellitus, hypertensive disease or coronary disease. Other physical examinations, including electrocardiogram, lung function examination and echocardiogram, were normal. The serum concentrations of Na+, K+, Ca2+ and glucose were all within the normal limits. Distant metastasis was not found by CT of the chest and abdomen.

Three patients underwent esophagectomy, whereas the other two patients (No. 4 and No. 5) underwent tumor resection by VATS. The mean operating time...
was 116 min (range: 95-148 min), and the mean blood loss was 176 mL (range: 30-300 mL). All tumors were completely resected. The tumor size was available for five patients, and ranged from 2 to 6 cm, with a mean size of 3.4 cm. The hematoxylin-eosin stained GISTs showed a rich variety of spindle cells (Figure 3). The immunohistochemical reactions for CD 117 were positive in all patients, and four patients were positive for CD 34 (Table 1). The mean length of postoperative hospital stay was 8.4 d (range: 6-12 d). All patients recovered and were discharged successfully.

The mean duration of follow-up was 48 mo (range, 29-72 mo). One patient (No. 3) was followed for 35.3 mo post-surgery, and evidence of a recurrent tumor in the bilateral lung was observed. However, this patient was not treated with imatinib and died after 5 mo. One patient was lost to follow-up, and three patients were asymptomatic and are currently being managed with close radiologic and clinical follow-up.

DISCUSSION

GISTs are common neoplasms of the digestive tract, and they frequently occur in the stomach and small intestine and less frequently in the esophagus. In the early stages of esophageal GISTs, patients often do not exhibit clear clinical symptoms. As the tumor grows, patients present with different symptoms that are dependent on tumor location and size, including progressive dysphagia, chest discomfort, reflux and heartburn feeling.

To our knowledge, the largest single center experience describing the surgical treatment of primary esophageal GISTs was described by Lee[17]. In recent years, the characteristics of GISTs have become increasingly recognized. Due to the submucosal location and rarity, it is not possible to determine whether a mass is benign or malignant using imaging examinations, including endoscopic ultrasound, esophageal barium imaging, chest X-rays and CT. However, imaging examinations are beneficial for assessing GISTs and improving detection of distant metastases. Preoperatively, the diagnosis of GISTs may be confirmed through endoscopy, combined with typical histomorphological findings, including atypical spindle shaped neoplastic cells within red endochylema, as well as through immunohistochemical staining for a CD 117+/EMA pattern. However, if a well-circumscribed, rounded or elliptical, submucosal tumor is detected during endoscopic procedures, a biopsy is rarely performed due to tumor cells releasing into thoracic cavity, leading to metastases[17]. Meanwhile, a biopsy might cause uncontrolled bleeding. With the advancement of technology and computers, 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) may be beneficial for the diagnosis of GISTs and might play a crucial role in the assessment and prediction of treatment responses in the future. The importance of FDG-PET consists of its ability to detect distant metastases and its high negative predictive value.

The differential diagnosis of an esophageal GIST includes malignant and benign tumors, including leiomyoma, hemangioma, schwannoma, leiomyosarcoma and papillary epithelioma. Primarily, they share similar clinical characteristics, endoscopic observation and radiographic features. Thus, histology and immunohistochemistry are the most significant tools for differentiating between these tumors. For example, GISTs are c-kit (CD117)-positive and SMA-negative. Thus, the presence of different markers in GISTs distinguishes them from other tumors.

The most successful and effective treatment for GISTs is surgery[22-24]. In the past, the majority of esophageal tumor excisions have been approached via thoracotomy. With the development of thoracoscopic surgery, surgery is increasing being performed by thoracoscopy due to decreased pain and blood[25-27]. There is some skepticism for malignant GISTs concerning lymph node clearance and efficacy due to the rarity of cases. Therefore, continuous efforts focusing on the benefits of VATS over open surgery are needed for more comparative studies. According to Lee, patients with well-circumscribed, benign tumors less than 5 cm in diameter should undergo VATS, and patients with invasive, aggressive tumors greater than 5 cm may require biopsy and esophagectomy[4]. In...
Table 1  Patient characteristics and treatment history

| Feature                      | Patient No. 1          | Patient No. 2          | Patient No. 3          | Patient No. 4          | Patient No. 5          |
|------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|
| Gender                       | Male                   | Male                   | Male                   | Male                   | Male                   |
| Age                          | 12                     | 49                     | 48                     | 57                     | 62                     |
| Presentation                 | Dysphagia              | Chest discomfort       | Dysphagia              | Dysphagia              | Asymptomatic           |
| Location of lesions          | Middle                 | Middle                 | Distal                 | Upper                  | Distal                 |
| Surgical procedure           | Thoracotomy            | Thoracotomy            | Thoracotomy            | VATS                   | VATS                   |
| Operating time (min)          | 148                    | 110                    | 122                    | 105                    | 95                     |
| Blood loss (mL)              | 300                    | 30                     | 300                    | 150                    | 100                    |
| Size of lesion (cm)          | 6 × 4                  | 2 × 1.5                | 6 × 5                  | 3 × 2                  | 1 × 2                  |
| Postoperative hospital stay (d)| 12                     | 6                      | 10                     | 7                      | 7                      |
| Time of intrathoracic drain (d)| 6                     | 4                      | 4                      | 3                      | 3                      |
| Cellular pattern             | Spindle                | Spindle                | Spindle                | Spindle                | Spindle                |
| Mitosis per 50 high power fields | 10                   | 0                      | 6                      | 1                      | 0                      |
| CD34                         | +                      | +                      | +                      | +                      | -                      |
| CD117                        | +                      | +                      | +                      | +                      | +                      |
| Desmin                       | -                      | -                      | -                      | -                      | -                      |
| S-100                        | -                      | -                      | -                      | -                      | -                      |
| SMA                          | -                      | -                      | -                      | -                      | -                      |
| Diagnosis                    | Malignant              | Benign                 | Malignant              | Benign                 | Benign                 |
| Follow-up (mo)               | -                      | 29                     | 40                     | 51                     | 72                     |
| Recurrence                   | -                      | No                     | Yes                    | No                     | No                     |
| Current status               | -                      | NED                    | Dead                   | NED                    | NED                    |

NED: No evidence of disease; VATS: Video-assisted thoracoscopic surgery.

the present case, surgical approaches were prepared depending on the characteristics of the tumor. If the tumor was benign, a total tumor excision was performed. For a malignant tumor, an esophagectomy and lymph node dissection involving radical dissection of the mediastinum was performed. Overall, three patients underwent esophagectomy, and two patients underwent VATS in our study. A 12-year-old boy, one of our rare cases, presented to our department with dysphagia for three months. Barium swallow was performed, which showed the presence of a tumor 6 cm in diameter at the middle thoracic esophagus. Reconstruction of the gastroesophageal junction after tumor resection was difficult and resulted in developmental immaturity of the digestive tract.

Based on the ability of imatinib to improve outcomes in GISTs, treatment strategies complementary to radical surgery have been extensively used. The optimal duration of preoperative imatinib may be as long as 6–12 mo[28]. However, due to tumor necrosis and cystic changes, preoperative imatinib may result in rupture or bleeding and increase the fragility of GISTs[29]. Adjuvant imatinib in patients with resection of GIST has consistently been shown to prevent recurrences and increase survival in many clinical studies[30,31]. However, all cases in these studies have been from the stomach or intestine. Because of the rarity of esophageal GISTs, the effectiveness of imatinib requires more comparative studies.

In conclusion, tumor resection was successfully performed and the diagnosis of GISTs was determined based on immunohistochemical findings. Long-term follow-up with radiological imaging is required to monitor the recurrence and metastasis of this type of tumor.

REFERENCES

1. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983; 7: 507-519 [PMID: 6625048]
2. Macias-Garcia F, Parada P, Martinez-Lesquereux L, Pintos E, Fraga M, Dominquez-Muñoz JE. Gastrointestinal stromal tumors (GISTs) of the colon. Rev Esp Enferm Dig 2010; 102: 388-390 [PMID: 20575602 DOI: 10.4321/S1130-01082010001800010]
3. Hassan I, You YN, Dozois EJ, Shayyan R, Smyrk TC, Okano SH, Donohue JH. Clinical, pathologic, and immunohistochemical characteristics of gastrointestinal stromal tumors of the colon and rectum: implications for surgical management and adjuvant therapies. Dis Colon Rectum 2006; 49: 609-615 [PMID: 16552495]
Clinical characteristics and surgical treatment of oesophageal gastrointestinal stromal tumours. Eur J Cardiothorac Surg 2010; 38: 223-227 [PMID: 20206541 DOI: 10.1016/j.ejcts.2010.01.040]

Emory TS, Sobin LH, Lukes E, Lee DH, O'Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumours: dependence on anatomic site. Am J Surg Pathol 1999; 23: 82-87 [PMID: 9888707 DOI: 10.1097/00000478-199901000-00009]

Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Intestinal cells of Cajal as precursors of gastrointestinal stromal tumours. Am J Surg Pathol 1999; 23: 377-389 [PMID: 10199467 DOI: 10.1097/00000478-199904000-00002]

Takahashi T, Nakajima K, Miyazaki Y, Miyazaki Y, Kurokawa Y, Yamasaki M, Miyata H, Takiguchi S, Nishida T, Mori M, Doki Y. Surgical Strategy for the Gastric Gastrointestinal Stromal Tumors (GISTs) Larger than 5 cm: Laparoscopic Surgery is Feasible, Safe, and Oncologically Acceptable. Surg Laparosc Endosc Percutan Tech 2015; 25: 114-118 [PMID: 24752159]

Blum MG, Bilimoria KY, Wayne JD, de Hoyos AL, Talamonti MS, Adley B. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors. Am Thorac Surg 2008; 77: 1717-1723 [PMID: 17954092 DOI: 10.1016/j.athoracsur.2007.05.071]

Markakis CG, Spartalis ED, Liarmakopoulos E, Kavoura EG, Tomos P. Esophageal gastrointestinal stromal tumor: diagnostic complexity and management pitfalls. Case Rep Surg 2013; 2013: 968394 [PMID: 23738166]

Qiu WQ, Zhang LC, Jiang P, Lu H, Shen ZY, Xue HB, Shen L, Ge ZZ, Cao H. Minimally invasive treatment of laparoscopic and endoscopic cooperative surgery for patients with gastrointestinal stromal tumors. J Dig Dis 2013; 14: 469-473 [PMID: 23701957 DOI: 10.1016/j.jdd.2012.10.007]

Jeong IH, Kim JL, Lee SR, Kim JH, Hwang JC, Shin SJ, Lee KM, Hur H, Han SU. Minimally invasive treatment of gastric gastrointestinal stromal tumors: laparoscopic and endoscopic approach. J Surg Oncol 2013; 107: 3117-3123 [PMID: 23716992 DOI: 10.3748/wjg.v19.i20.3117]

Dholakia C, Gould J. Minimally invasive resection of gastrointestinal stromal tumors. Surg Clin North Am 2008; 88: 1009-118, vi [PMID: 18790151 DOI: 10.1016/j.suc.2008.05.006]

von Mehren M, Benjamins RJ, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoon KN, George S, Gonzalez R, Heslin MJ, Kane JM, Mayerson J, McCary SV, Meyer C, O'Donnell RJ, Paz B, Pfeifer JD, Pollock RE, Randall RJL, Riedel RE, Schuetze S, Schupak KD, Schwartz HS, Shankar V, Van Tine BA, Wayne J, Sundar H, McMillian NR. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012; 10: 951-960 [PMID: 22878820]

Yip D, Zalcberg J, Ackland S, Barbour AP, Desai J, Fox S, Kotaske D, McArthur G, Smithers BM. Controversies in the management of gastrointestinal stromal tumours. Asia Pac J Clin Oncol 2014; 10: 216-227 [PMID: 24637914 DOI: 10.1111/ajco.12187]

Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104 [PMID: 19301377 DOI: 10.1016/S0140-6736(09)60860-9]

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wahlmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097-1104 [PMID: 19301377 DOI: 10.1016/S0140-6736(09)60860-9]
